Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for early breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study
Archives of Medical Science, 05/10/2012
Piotrowski G et al. – One out of five treated patients discontinues trastuzumab in an adjuvant setting due to cardiac complications. LV dysfunction is the most frequent. Routine cardiac monitoring should be obligatory.